
Embracer Group - Transformative licensing deal saves the day

Redeye updates its view on Embracer post its Q3 report, which showed solid net sales but weaker profitability. However, Embracer reiterated its guidance for FY 2022/2023e-2023/2024e.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Embracer Group - Transformative licensing deal saves the day](#)